Linda Llewelyn Sells 648 Shares of Health Catalyst, Inc. (NASDAQ:HCAT) Stock

Health Catalyst, Inc. (NASDAQ:HCATGet Rating) insider Linda Llewelyn sold 648 shares of the stock in a transaction that occurred on Friday, July 15th. The stock was sold at an average price of $16.06, for a total value of $10,406.88. Following the transaction, the insider now owns 58,029 shares in the company, valued at approximately $931,945.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Linda Llewelyn also recently made the following trade(s):

  • On Wednesday, June 15th, Linda Llewelyn sold 648 shares of Health Catalyst stock. The stock was sold at an average price of $12.20, for a total value of $7,905.60.
  • On Monday, May 16th, Linda Llewelyn sold 1,860 shares of Health Catalyst stock. The stock was sold at an average price of $15.87, for a total value of $29,518.20.

Health Catalyst Stock Performance

NASDAQ:HCAT opened at $16.03 on Friday. Health Catalyst, Inc. has a one year low of $11.25 and a one year high of $59.50. The stock has a market cap of $868.67 million, a PE ratio of -5.17 and a beta of 1.07. The stock has a 50 day moving average price of $14.84 and a 200 day moving average price of $21.89.

Health Catalyst (NASDAQ:HCATGet Rating) last posted its quarterly earnings results on Tuesday, May 10th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.03. The firm had revenue of $68.09 million during the quarter, compared to analysts’ expectations of $66.01 million. Health Catalyst had a negative return on equity of 19.88% and a negative net margin of 57.95%. The business’s revenue for the quarter was up 21.9% on a year-over-year basis. During the same quarter last year, the firm earned ($0.37) earnings per share. As a group, analysts predict that Health Catalyst, Inc. will post -1.83 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. BTIG Research decreased their target price on Health Catalyst from $60.00 to $50.00 and set a “buy” rating on the stock in a research report on Friday, March 25th. Canaccord Genuity Group decreased their target price on Health Catalyst from $35.00 to $17.00 in a research report on Wednesday, May 11th. Citigroup decreased their target price on Health Catalyst from $45.00 to $25.00 in a research report on Wednesday, May 11th. Royal Bank of Canada decreased their target price on Health Catalyst from $35.00 to $19.00 in a research report on Wednesday, May 11th. Finally, Piper Sandler decreased their target price on Health Catalyst from $38.00 to $21.00 in a research report on Wednesday, May 11th. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Health Catalyst has a consensus rating of “Buy” and an average price target of $35.25.

Institutional Investors Weigh In On Health Catalyst

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Stratos Wealth Partners LTD. acquired a new stake in Health Catalyst during the first quarter worth $2,287,000. abrdn plc increased its stake in Health Catalyst by 10.1% during the fourth quarter. abrdn plc now owns 1,097,447 shares of the company’s stock worth $43,481,000 after acquiring an additional 100,829 shares during the last quarter. Renaissance Technologies LLC increased its stake in Health Catalyst by 39.6% during the fourth quarter. Renaissance Technologies LLC now owns 279,369 shares of the company’s stock worth $11,069,000 after acquiring an additional 79,300 shares during the last quarter. Exchange Traded Concepts LLC increased its stake in Health Catalyst by 20.1% during the first quarter. Exchange Traded Concepts LLC now owns 83,034 shares of the company’s stock worth $2,170,000 after acquiring an additional 13,907 shares during the last quarter. Finally, Swiss National Bank increased its stake in Health Catalyst by 13.6% during the fourth quarter. Swiss National Bank now owns 95,100 shares of the company’s stock worth $3,768,000 after acquiring an additional 11,400 shares during the last quarter. Institutional investors and hedge funds own 97.53% of the company’s stock.

About Health Catalyst

(Get Rating)

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its offerings include data and analytics platform, a commercial-grade data and analytics platform for the healthcare sector; AI and data science, providing integration of AI into existing business intelligence tools, increasing analytics accuracy; population health management identifies improvement across the care continuum as well as actionable guidance for success and automated workflows; financial transformation providing costing and labor productivity insights and revenue capture; quality and safety improvement using clinical quality and patient safety data, analytics, and expert services; and national data ecosystem for thought leadership and mutual knowledge exchange to transform care delivery through next-gen insights.

Featured Stories

Insider Buying and Selling by Quarter for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.